Noemí Eiris
Research Subjects
Noemí Eiris has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Rubén Queiro
Hospital Universitario Central de Asturias
8 shared publications - Jorge Santos-Juanes
Dermatology Service, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain
6 shared publications Eliecer Coto
Hospital Universitario Central Asturias
4 shared publications- Leire González-Lara
Department of Dermatology Ambroise Paré Hospital Boulogne‐Billancourt France
4 shared publications Pablo Coto-Segura
Departamento Dermatología, Hospital Alvarez Buylla, Mieres, Spain
4 shared publicationsAna Batalla
Servicio de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
3 shared publications
Latest Publications
- Open Access
Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)
Background: Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations. Methods: We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS). This study updates previous findings with a larger sample size (n = 372) and longer follow-up. We assessed absolute Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and the Dermatology Life Quality Index (DLQI) improvements, as well as safety, in patients with moderate-to-severe plaque psoriasis. Results: The cohort included a large population of patients with a high prevalence of comorbidities and prior biologic exposure. Effectiveness was high, with a significant proportion of patients achieving PASI < 1. Compared to recent real-world data, our cohort demonstrates superior complete clearance rates (PASI < 1) and includes a comprehensive DLQI assessment. Notably, 79 patients were aged ≥65 years, confirming the drug’s utility in the elderly. Safety was consistent with previous reports, with no new signals detected. Conclusions: Tildrakizumab shows robust effectiveness and safety in a complex, bio-experienced real-world population. The lack of clinical predictors of response suggests a need for future pharmacogenetic exploration.
Open AccessReal-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)
Background: Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations. Methods: We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS). This study updates previous findings with a larger sample size (n = 372) and longer follow-up. We assessed absolute Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and the Dermatology Life Quality Index (DLQI) improvements, as well as safety, in patients with moderate-to-severe plaque psoriasis. Results: The cohort included a large population of patients with a high prevalence of comorbidities and prior biologic exposure. Effectiveness was high, with a significant proportion of patients achieving PASI < 1. Compared to recent real-world data, our cohort demonstrates superior complete clearance rates (PASI < 1) and includes a comprehensive DLQI assessment. Notably, 79 patients were aged ≥65 years, confirming the drug’s utility in the elderly. Safety was consistent with previous reports, with no new signals detected. Conclusions: Tildrakizumab shows robust effectiveness and safety in a complex, bio-experienced real-world population. The lack of clinical predictors of response suggests a need for future pharmacogenetic exploration.
- 2 July 2019
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 23 (5) , 627-633
NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis
Nuclear factor (NF)-κB is an essential mediator of the tumor necrosis factor (TNF) pathway, and has been implicated in psoriasis. NFKBIZ is a nuclear inhibitor of NF-κB with a prominent role in the pathogenesis of psoriasis. The genetic variation at the NFKBIZ gene has been associated with the risk of developing psoriasis, and could also contribute to defining the response to anti-TNF biological drugs.
- 2 July 2019
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 23 (5) , 627-633
NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis
Nuclear factor (NF)-κB is an essential mediator of the tumor necrosis factor (TNF) pathway, and has been implicated in psoriasis. NFKBIZ is a nuclear inhibitor of NF-κB with a prominent role in the pathogenesis of psoriasis. The genetic variation at the NFKBIZ gene has been associated with the risk of developing psoriasis, and could also contribute to defining the response to anti-TNF biological drugs.
- 30 November 2018
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 145 (12) , S330-S331
Variantes génétiques de la voie de signalisation NF-kb et risque de psoriasis : données d’une cohorte espagnole
- 30 November 2018
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 145 (12) , S330-S331
Variantes génétiques de la voie de signalisation NF-kb et risque de psoriasis : données d’une cohorte espagnole
- 1 May 2017
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 76 (5) , e175-e176
Surgical staples for hemostasis during scalp surgery
- 1 May 2017
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 76 (5) , e175-e176
Surgical staples for hemostasis during scalp surgery
- 1 May 2017
- Published by Elsevier in Human Immunology
- Vol. 78 (5-6) , 435-440
NFKBIZ in Psoriasis: Assessing the association with gene polymorphisms and report of a new transcript variant
- 1 May 2017
- Published by Elsevier in Human Immunology
- Vol. 78 (5-6) , 435-440
NFKBIZ in Psoriasis: Assessing the association with gene polymorphisms and report of a new transcript variant
- 1 March 2017
- Published by Elsevier in Journal of Dermatological Science
- Vol. 85 (3) , 241-246
Treatment of hidradenitis suppurativa with intralesional photodynamic therapy with 5-aminolevulinic acid and 630nm laser beam
- 1 March 2017
- Published by Elsevier in Journal of Dermatological Science
- Vol. 85 (3) , 241-246
Treatment of hidradenitis suppurativa with intralesional photodynamic therapy with 5-aminolevulinic acid and 630nm laser beam
- 1 December 2016
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 75 (6) , e207-e208
Sudden edematous exudative erythema in a waterfall pattern
- 1 December 2016
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 75 (6) , e207-e208
Sudden edematous exudative erythema in a waterfall pattern
- 27 September 2016
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 18 (1) , 76-80
IL17RA gene variants and anti-TNF response among psoriasis patients
The Pharmacogenomics Journal is dedicated to the rapid publication of original research on basic pharmacogenomics research and its clinical applications.
- 27 September 2016
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 18 (1) , 76-80
IL17RA gene variants and anti-TNF response among psoriasis patients
The Pharmacogenomics Journal is dedicated to the rapid publication of original research on basic pharmacogenomics research and its clinical applications.
- 1 September 2016
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 75 (3) , e107
Suturing the nail plate during matricectomy
- 1 September 2016
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 75 (3) , e107
Suturing the nail plate during matricectomy
- 6 July 2015
- Published by AMPCo in Medical Journal of Australia
- Vol. 203 (1) , 41-42
Tinea hidden by a vemurafenib‐induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone
While vemurafenib induces ultraviolet A photosensitivity, it is important to consider alternative diagnoses when minimal response to therapy is attained
- 6 July 2015
- Published by AMPCo in Medical Journal of Australia
- Vol. 203 (1) , 41-42
Tinea hidden by a vemurafenib‐induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone
While vemurafenib induces ultraviolet A photosensitivity, it is important to consider alternative diagnoses when minimal response to therapy is attained